Your browser doesn't support javascript.
loading
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin.
Han, Nanumi; Wada, Haruka; Kobayashi, Takuto; Otsuka, Ryo; Seino, Ken-Ichiro.
Afiliação
  • Han N; Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Wada H; Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Kobayashi T; Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Otsuka R; Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Seino KI; Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
Oncoimmunology ; 12(1): 2238499, 2023.
Article em En | MEDLINE | ID: mdl-37533702
ABSTRACT
Interleukin-34 (IL-34) has been known as a factor that is involved with tumor progression and therapeutic resistance. However, there are limitations to addressing the mechanism of how IL-34 induces therapeutic resistance. Here, we show a mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiotherapy using X-ray and chemotherapy by Oxaliplatin. This research demonstrates that IL-34 immunologically changes the tumor microenvironment after treatments with radiation or chemotherapeutic agents such as oxaliplatin. We identified the changes in immune cells using flow cytometry and immunofluorescent (IF) staining, which are up-regulated upon the existence of IL-34. Overall, these findings demonstrate the possibility of IL-34 blockade as a novel combination therapy for cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucinas / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucinas / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA